Introduction
1 Cardiac hypertrophy is elicited by endothelin (ET)-1 (Suzuki et al., 1990; Yorikane et 2 al., 1993; Ito et al., 1997; Koleitis et al., 2013; Miyauchi and Goto, 2013) as well as other 3 neurohumoral factors, hemodynamic overload, and oxidative stress. One of the 4 common intracellular pathways of them is the phosphorylation cascade of MEK 5 signaling. Peptidyl-prolyl cis-trans isomerase 1 (Pin1) is a highly conserved enzyme that 6 isomerizes specific phosphorylated Ser/Thr-Pro bonds in certain proteins, inducing 7 conformational changes (Lu et al., 1996) . It has been reported that Pin1 has the binding 8 activity to the pSer/Thr-Pro pocket of target protein and that Pin1 catalyzes such portion.
9
Both of these activities are exerted when the Ser-16 residue of Pin1 is 10 dephosphorylated; on the other hand, these activities are inhibited when the residue is 11 phosphorylated (Lu et al., 2007) . The family of proline-directed protein kinases 12 containing a major regulatory phosphorylation motif (pSer/Thr-Pro) includes c-Jun, Akt, 13 cyclin dependent kinases, Raf-1, SMAD2/SMAD3, etc., which play an important role in 14 the regulation of cell proliferation, tumorigenesis, neurological disorders, and 15 autoimmune and inflammatory diseases (Lee et al., 2011) .
16
The endothelin (ET) system consists of two G protein coupled-receptors, ET type A 17 receptor and ET type B receptor, and three endogenous ligands, 18 (Davenport, 2002; Horinouchi et al., 2013; Koleitis et al., 2013; Miyauchi and Goto, 19 2013). ET-1, a potent vasoconstrictive peptide produced by endothelial cells 20 (Yanagisawa et al.,1988) , is also produced by cardiomyocytes and contributes to the 21 development of cardiac hypertrophy (Ito et al., 1991; Yorikane et al., 1993; Koleitis et al., 22 2013; Miyauchi and Goto, 2013) . We reported that the production of ET-1 is markedly 23 increased in the failing hearts of rats with chronic heart failure (Sakai et al., 1996a;  24 Sakai et al., 1996b) and that the enhancement of myocardial ET-1 contributes to the 25 modulation of the cardiac function (Sakai et al., 1996a) and cardiac hypertrophy at the 26 However, there is no report whether the Pin1 activation is involved in cardiomyocyte 1 hypertrophy provoked by ET-1; therefore, we hypothesized that the activation of Pin1 2 activity would contribute to the ET-1-induced cardiomyocyte hypertrophy. In addition, 3 there is no report whether the inhibitory effect of statins on the ET-1-induced 4 cardiomyocyte hypertrophy is mediated through the modulation of the Pin1 activity. The 5 aim of this study was to reveal these questions.
7

Materials and Methods
8
Adenovirus vectors
Human Pin1 cDNA cloned from 293A cells by PCR using the 9 following primers, (Forward) 5'-CACCATGGCGGACGAGGAGAAGCT-3' and (Reverse) 18 min. The blots were visualized with an enhanced chemiluminescence detection system 19 (GE Healthcare), exposed to X-ray film or captured by CCD camera system (AE-6981,
20
Atto Corporation, Tokyo, Japan), and analyzed by CS Analyzer (Atto Corporation). The
21
following was used as the first antibodies: rabbit anti-Pin1, rabbit anti-phospho-Pin1, Figure 3B ), suggesting the inhibition of the JNK pathway by fluvastatin; however, 5 fluvastatin did not alter the phospho-ERK level augmented by ET-1 ( Figure 3A) . These 
17
Cyclin D1, whose function is suppressed by statins, is also known to be a target of Pin1 18 (Liou et al., 2002) ; therefore, there is a possibility that the involvement of cyclin D1 19 inhibition by fluvastatin on the anti-hypertrophy effect is partly mediated via the 20 suppression of Pin1.
21
In the transient transfection assay using Pin1 adenovirus vector, the gain of the Pin1 22 function by the Pin1 overexpression caused cardiomyocyte hypertrophy, whereas 23 fluvastatin attenuated the Pin1-induced hypertrophy. The ET-1-induced reduction in 24 phospho-Pin1 level was reversed by fluvastatin ( Fig 5) , whereas the expression level of 25 phospho-Pin1 did not differ significantly between in fluvastatin treated Pin1 group and in 26 vehicle-treated Pin1 group ( Figure 6E ). Therefore, we consider a mechanism for an 1 inhibition of Pin1-induced cardiomyocyte hypertrophy by fluvastatin with no alteration of 2 the phospho-Pin1 level as followings. Because it has been reported that 3 death-associated protein kinase 1 (DAPK1) inhibits the catalytic activity of Pin1 (Lee et   4 al., 2011), it would be suspected that the suppressive effect of statins on Pin1-mediated 5 hypertrophic response is partly be attributed to the magnitude of DAPK1 activation.
6
Alternatively, the following discussion may be also possible. The overexpression 7 experiment of Pin1 transgene, which was forcedly expressed by CMV promoter and out 8 of the transcriptional control by primarily or secondarily statin-regulated transcriptional 9 factors, is an artificial condition. Thus, the transgene product may be a large amount 10 compared with the endogenous Pin1 protein; therefore, we could not detect a significant 11 difference of phospho-Pin1 expression level between in vehicle-treated Pin1 group and 12 in fluvastatin-treated Pin1. In addition to above consideration, the precise mechanism 13 for statins in the inactivation of Pin1 function still remains to be resolved.
15
Conclusion
16
The present study revealed for the first time that (1) 
21
These findings firstly suggest that Pin1 is an important molecule for aggravating cardiac 22 hypertrophy and that the inhibition of the Pin1 function by HMG-CoA reductase 23 inhibitors is a novel mechanism for pleiotropic effects of them.
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